Cipla Ltd
Fortune 500 2024
+ 14 More
+ 14 More
Share
Share
OVERVIEW
FINANCIALS
NEWS
About
Cipla, also known as Chemical, Industrial & Pharmaceutical Laboratories, is one of India’s multinational pharmaceutical companies. It was founded and chaired by K.A. Hamied in 1935, after which he was succeeded by Y.K. Hamied and M. K. Hamied. Cipla is currently headquartered in Mumbai and has extended its presence to more than 80 countries. Cipla offers an array of more than 1500 therapeutic products that echo its guiding purpose and vision to “care for life”. Its antiretroviral therapy in the HIV/AIDS movement provided an affordable, inclusive, and accessible contribution to the disease, echoing its deep-rooted humanitarian approach to providing quality healthcare.
Incorporation Year: 1935
Headquarters: Mumbai, Maharashtra
Top Management: Yusuf Hamied
Industry: Pharma
Website: www.cipla.com
Featured In Fortune India Ranking
Fortune 500 India
#92(2024)
#99(2023)
#80(2022)
#75(2021)
#82(2020)
#91(2019)
#100(2018)
#90(2017)
#94(2016)
#111(2015)
#121(2014)
#126(2013)
#141(2012)
#128(2011)
#118(2010)
#92(2024)#99(2023)#80(2022)#75(2021)#82(2020)#91(2019)#100(2018)#90(2017)#94(2016)#111(2015)#121(2014)#126(2013)#141(2012)#128(2011)#118(2010)
Ranking Trend Fortune 500 India
Financial Data 2024
Revenue
26,458
(INR Cr)
Net Operating Income
25,774
(INR Cr)
Assets
27,621
(INR Cr)
Profit
4,122
(INR Cr)
Net Worth
26,706
(INR Cr)
Fortune India Coverage
Financial Data
RevenueNet Operating IncomeProfitAssetsNet Worth
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 26458 13.4% | 23325 2.4% | 22769 16.1% | 19618 10.7% | 17721 5.5% | 16792 6.6% | 15746 8.5% | 14512 4.1% | 13935 17.5% | 11855 12.9% | 10503 18.9% | 8832 23.4% | 7155 9.2% | 6554 7.9% | 6073 11.9% | 5429 - |
| Net Operating Income (INR Cr) | 25774 13.28% | 22753 4.55% | 21763 13.59% | 19160 11.84% | 17132 4.70% | 16362 7.96% | 15156 5.29% | 14394 4.38% | 13790 21.55% | 11345 11.52% | 10173 22.88% | 8279 17.93% | 7021 11.02% | 6324 17.99% | 5360 8.04% | 4961 23.69% |
| Profit (INR Cr) | 4122 47.1% | 2802 11.3% | 2517 4.7% | 2405 55.5% | 1547 1.2% | 1528 8.3% | 1411 40.2% | 1006 -26.0% | 1360 15.2% | 1181 -15.0% | 1388 -10.1% | 1545 35.0% | 1144 15.6% | 990 -8.6% | 1083 40.4% | 771 - |
| Assets (INR Cr) | 27621 11.4% | 24785 10.5% | 22425 7.4% | 20878 7.9% | 19351 -4.5% | 20253 6.8% | 18961 9.1% | 17374 0.1% | 17356 34.6% | 12899 12.6% | 11458 13.8% | 10066 30.2% | 7729 6.8% | 7239 22.4% | 5916 11.9% | 5288 - |
| Net Worth (INR Cr) | 26706 14.1% | 23408 12.3% | 20842 13.7% | 18327 16.3% | 15763 5.0% | 15012 5.5% | 14229 13.4% | 12544 8.9% | 11516 6.7% | 10793 7.5% | 10041 11.5% | 9010 18.1% | 7630 14.6% | 6657 12.8% | 5902 36.0% | 4339 15.8% |
| Employee Cost (INR Cr) | 4310 12.5% | 3830 8.5% | 3530 8.6% | 3252 7.4% | 3027 6.0% | 2857 6.2% | 2690 2.1% | 2634 8.2% | 2434 23.7% | 1968 27.5% | 1543 48.9% | 1036 34.1% | 773 36.6% | 566 77.3% | 319 17.6% | 271 - |
| Interest Cost (INR Cr) | 90 | 110 | 106 | 161 | 197 | 168 | 114 | 159 | 207 | 168 | 146 | 34 | 38 | 25 | 28 | 52 |
| Cash & Bank Balance (INR Cr) | 875 | 1565 | 1928 | 1401 | 1004 | 619 | 966 | 624 | 871 | 564 | 176 | 143 | 90 | 96 | 62 | 53 |
| Total Debt (INR Cr) | 559 | 803 | 1056 | 2014 | 2816 | 4316 | 4098 | 4113 | 5202 | 1703 | 1248 | 967 | 29 | 572 | 5 | 940 |
Key Financial Ratios
Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 15.6% | 12.0% | 11.1% | 12.3% | 8.7% | 9.1% | 9.0% | 6.9% | 9.8% | 10.0% | 13.2% | 17.5% | 16.0% | 15.1% | 17.8% | 14.2% |
| Profit As % Of Assets | 14.9% | 11.3% | 11.2% | 11.5% | 8.0% | 7.5% | 7.4% | 5.8% | 7.8% | 9.2% | 12.1% | 15.4% | 14.8% | 13.7% | 18.3% | 14.6% |
| Profit As % Of Networth | 15.4% | 12.0% | 12.1% | 13.1% | 9.8% | 10.2% | 9.9% | 8.0% | 11.8% | 10.9% | 13.8% | 17.2% | 15.0% | 14.9% | 18.3% | 17.8% |
| Interest Cost to EBITDA % | 1.5% | 2.3% | 2.4% | 3.8% | 6.2% | 5.4% | 4.2% | 6.4% | 8.3% | 7.8% | 6.8% | 1.5% | 2.3% | 1.8% | 2.6% | 7.0% |
| Debt to Equity Ratio | 0.02 | 0.03 | 0.05 | 0.11 | 0.18 | 0.29 | 0.29 | 0.33 | 0.45 | 0.16 | 0.12 | 0.11 | 0.00 | 0.09 | 0.00 | 0.22 |
| RONW | 16.6% | 12.8% | 13.1% | 14.1% | 10.1% | 10.3% | 10.6% | 7.9% | 12.5% | 12.0% | 14.9% | 18.6% | 16.0% | 15.4% | 21.1% | 19.1% |
| ROCE | 22.3% | 17.8% | 16.8% | 17.4% | 12.2% | 11.7% | 10.0% | 7.2% | 13.0% | 15.1% | 18.9% | 24.0% | 19.9% | 18.1% | 24.2% | 19.8% |